Alembic Pharmaceuticals Limited (APLLTD)
Press Release
Press Release - Q2FY27
- Revenue from operations increased 36% YoY to Rs. 2603 Cr
- EBITDA up 78% YoY to Rs. 578 Cr; margin at 22%
- PAT up 81% YoY to Rs. 335 Cr
- India Branded Business grew 14% YoY to Rs. 725 Cr; strong growth in chronic therapies
- US Formulations grew 77% with 3 new launches; Ex-US up 12%
- API business grew 39% to Rs. 436 Cr
- MD: "Well positioned to sustain growth and create long-term value"
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 APLLTD — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add APLLTD to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alembic Pharmaceuticals Limited
Important.
The summary above is generated automatically from Alembic Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.